This report provides comprehensive coverage of the global CNS market,
incorporating disease overview, epidemiological analyses of the major
indications, and market dynamics. Resistors and drivers are examined along
with the most promising areas of growth. Current leading CNS brands are
assessed and five of the market' s leading players are profiled.
Features and benefits
Assess the forecast epidemiology and development of the CNS disorders
across the 7MM.
Analyze the dynamics of the global CNS market and understand the impact of
key R&D events, market trends, and issues.
Gain up-to-date competitive intelligence and understand the major issues
affecting key pharmaceutical marketers and product development.
Predict revenues for major currently marketed and pipeline CNS products
over from 2010 to 2016.
Develop strategies for success in the future CNS market.
Highlights
Antipsychotics were the largest CNS drug class with $24.2bn sales, a 33.9%
share of the market in 2010. Patent expirations of key brands Seroquel and
Zyprexa will form the main resistors to segmental growth through 2016.
Imminent patent expiries for major brands have resulted in companies
investigating new indications and re-formulation strategies to extend patents
and safeguard revenue streams. Companies have also begun to manufacture and
market generic versions of their products.
Of the indications in the CNS category, Alzheimer' s disease (AD) represents
the main area of R&D interest for pharmaceutical companies, with an estimated
288 compounds in various stages of development.
Your key questions answered
What are the drivers and resistors of the CNS market worldwide?
What market and pipeline developments are shaping the strategies of
leading pharmaceutical companies in the CNS market?
What is the forecast commercial potential of the most promising compounds
in clinical development?
Who were the leading players in the global CNS market in 2010?
How have recent launches from companies such as Allergan, P&G, GSK, Eisai,
and Novartis performed?
Table of Contents
Table of Contents
About the author
Disclaimer
EXECUTIVE SUMMARY
Overview and epidemiology of CNS disorders
Industry structure and market dynamics
Pipeline analysis
Competitive landscape
Overview and epidemiology of CNS disorders
Summary
Introduction
Major depressive disorder (MDD)
Epilepsy
Schizophrenia
Alzheimer' s disease
Parkinson' s disease
Migraine
Insomnia
Attention-deficit hyperactivity disorder
Industry structure and market dynamics
Summary
Introduction
Global CNS market
Key events
Market drivers
Market challenges
Leading CNS brands
Market analysis by drug class
Antipsychotics
Antidepressants
Anti-epileptics
Alzheimer' s disease
Psychostimulants
Parkinson' s disease
Hypnotic/sedatives
Anti-migraine drugs
Genericization in the CNS market
Global CNS sales forecast
Pipeline analysis
Summary
Introduction
Key trends in R&D
Disease modifying therapies hold promise in Alzheimer' s disease
Anti-migraine market sees newer therapies after many years
Novel drugs with differentiated clinical profiles represent a sizeable
market opportunity
SSRI generics and branded SNRIs are changing the depression landscape
Label expansions of antidepressants provide a significant opportunity
for growth
Table: Forecast epidemiology of MDD in the 7MM, 2010
Table: Prevalence of epilepsy in the 7MM, 2010
Table: Forecast epidemiology of epilepsy in the 7MM, 2010
Table: Prevalence of schizophrenia in the 7MM, 2010
Table: Forecast epidemiology of schizophrenia in the 7MM, 2010
Table: Prevalence of Alzheimer' s disease in the 7MM, 2010
Table: Forecast epidemiology of Alzheimer' s in the 7MM, 2010
Table: Prevalence of Parkinson' s disease in the 7MM, 2010
Table: Forecast epidemiology of Parkinson' s disease in the 7MM, 2010
Table: Prevalence of migraine in the 7MM, 2010
Table: Forecast epidemiology of migraine in the 7MM, 2010
Table: Prevalence of insomnia in the 7MM, 2010
Table: Forecast epidemiology of insomnia in the 7MM, 2010
Table: Prevalence of ADHD in adults in the 7MM, 2010
Table: Prevalence of ADHD in children in the 7MM, 2010
Table: Forecast epidemiology of ADHD in adults in the 7MM, 2010
Table: Forecast epidemiology of ADHD in children in the 7MM, 2010
Table: Regional performance of CNS market, 2006 - 2010
Table: Leading 10 CNS products, 2010
Table: Sales performance of various CNS drug class, 2010
Table: Leading antipsychotic products, 2010
Table: Leading antidepressant products, 2010
Table: Leading anti-epileptics products, 2010
Table: Leading anti-Alzheimer' s products, 2010
Table: Leading psychostimulants products, 2010
Table: Leading anti-Parkinson' s products, 2010
Table: Leading hypnotic/sedative drugs, 2010
Table: Leading anti-migraine products, 2010
Table: Patent expirations of key CNS brands
Table: Forecast sales of CNS drug classes ($m), 2010 - 16
Table: CNS market forecast for Top 10 brands ($m), 2010 - 16
Table: Global CNS pipeline by indication and stage of development, May 2011
Table: An overview of Silenor
Table: An overview of Botox
Table: An overview of Potiga/Trobalt
Table: An overview of Stedesa
Table: An overview of Valdoxan/Thymanax
Table: An overview of lurasidone
Table: An overview of Levadex
Table: Clinical trial data points for Levadex
Table: An overview of bapineuzumab
Table: An overview of solanezumab
Table: An overview of telcagepant
Table: An overview of RG1678/RO4917838
Table: An overview of TC-5214
Table: An overview of LY2216684
Table: An overview of MK-4305
Table: An overview of IPX066
Table: Sales forecast for leading drugs in development ($m), 2010 - 16
Table: Leading players of the CNS market 2010*
Table: Leading CNS brands of Lilly , 2010
Table: Lilly' s CNS R&D product pipeline, January 2011
Table: Leading CNS brands of Pfizer , 2010
Table: Pfizer' s CNS R&D product pipeline, May 2011
Table: Leading CNS brands of AstraZeneca , 2010
Table: AstraZeneca ' s CNS R&D product pipeline , January 2011
Table: Leading CNS brands of J&J , 2010
Table: J&J' s CNS R&D product pipeline, April 2011
Table: Leading CNS brands of GSK , 2010
Table: GSK' s CNS R&D product pipeline, February 2011
FIGURES
Figure: Schizophrenia: classification of symptoms
Figure: Typical treatment patterns in the treatment of schizophrenia
Figure: Different stages of Alzheimer' s disease
Figure: Typical treatment patterns in the treatment of migraine
Figure: Selected late-stage, filed and recently launched CNS drugs
The CNS Market Outlook to 2016 published by Business Insights in July 13, 2011. This report consists of Pages: 170 and the price starts from US $ 3835.
